Promising results for AlgoTherapeutics’ ATX01 in chemo-induced peripheral neuropathy
French clinical-stage biotech AlgoTherapeutics (AlgoTx) today announced the completion of its 276 patient Phase II trial, known as ACT, with ATX01 in chemotherapy-induced peripheral neuropathy (CIPN).
Conducted under the guidance of Professor Guido Cavaletti (University of Milano-Bicocca, Italy), ACT is an international, double-blind, placebo-controlled evaluation of the efficacy and safety of two concentrations of ATX01 in patients suffering from CIPN, a common side effect of neurotoxic cancer treatments caused by nerve degeneration
AlgoTx’s ATX01 product has wide potential applicability beyond CIPN, in other diseases where peripheral neuropathic pain is a major issue. These include erythromelagia and diabetic peripheral neuropathy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze